Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

Read more breaking news



Chiltern says strategic deals are good for the CRO sector

By Gareth Macdonald , 30-Jun-2011
Last updated on 04-Jul-2011 at 10:22 GMT2011-07-04T10:22:14Z

Chiltern says strategic deals are good for the CRO sector

Chiltern says that strategic partnering in the contract research sector enables CROs to plan for the longer term and is having a tangible impact on brining drugs to market. spoke with Aize Smink, Chiltern’s senior executive VP, global clinical development, who said that the drug industry’s need for efficiency is driving the formation of such deals.

He explained that these types of collaboration are not limited to Big Pharma, citing the UK-headquartered CROs agreement with a number of mid-sized drug makers as evidence.

“[Strategic partnering] allows us to focus on the long term and look at process improvement in a collaborative way with our pharma partners. So it also drives progress for CROs in that sense.”

Related products

Happy Holidays 2014 from William Reed Business Media!

The holidays are fast upon us, so let’s put ‘business’ to one side and...

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

A bitter pill to swallow: young people dislike tablets more than old

Thomas Hein

Director, Sales & Business Development, Hermes

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Key Industry Events